دورية أكاديمية
A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.
العنوان: | A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. |
---|---|
المؤلفون: | Gillis JL; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; South Australian Health and Medical Research Institute, Adelaide, Australia., Hinneh JA; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; South Australian Health and Medical Research Institute, Adelaide, Australia.; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Ryan NK; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; South Australian Health and Medical Research Institute, Adelaide, Australia., Irani S; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; South Australian Health and Medical Research Institute, Adelaide, Australia., Moldovan M; South Australian Health and Medical Research Institute, Adelaide, Australia., Quek LE; School of Mathematics and Statistics, Charles Perkins Centre, Faculty of Science, The University of Sydney, Camperdown, Australia., Shrestha RK; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Flinders Health and Medical Research Institute, Flinders University, College of Medicine and Public Health, Bedford Park, Australia.; Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, Australia.; Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, Australia., Hanson AR; Flinders Health and Medical Research Institute, Flinders University, College of Medicine and Public Health, Bedford Park, Australia., Xie J; Flinders Health and Medical Research Institute, Flinders University, College of Medicine and Public Health, Bedford Park, Australia., Hoy AJ; School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia., Holst J; School of Medical Sciences and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Centenera MM; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; South Australian Health and Medical Research Institute, Adelaide, Australia.; Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, Australia., Mills IG; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, United Kingdom.; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom., Lynn DJ; South Australian Health and Medical Research Institute, Adelaide, Australia.; Flinders Health and Medical Research Institute, Flinders University, College of Medicine and Public Health, Bedford Park, Australia., Selth LA; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Flinders Health and Medical Research Institute, Flinders University, College of Medicine and Public Health, Bedford Park, Australia.; Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, Australia.; Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, Australia., Butler LM; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; South Australian Health and Medical Research Institute, Adelaide, Australia.; Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, Australia. |
المصدر: | ELife [Elife] 2021 Aug 12; Vol. 10. Date of Electronic Publication: 2021 Aug 12. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Cambridge, UK : eLife Sciences Publications, Ltd., 2012- |
مواضيع طبية MeSH: | Glyceraldehyde-3-Phosphate Dehydrogenases/*metabolism , Prostatic Neoplasms/*metabolism , Receptors, Androgen/*metabolism, AMP-Activated Protein Kinases/metabolism ; Acetyl-CoA Carboxylase/metabolism ; Cell Line ; Emodin/analogs & derivatives ; Feedback ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Male ; Mechanistic Target of Rapamycin Complex 1/metabolism ; Pentose Phosphate Pathway ; Prostatic Neoplasms/genetics ; Signal Transduction ; Sterol Regulatory Element Binding Protein 1/metabolism |
مستخلص: | Alterations to the androgen receptor (AR) signalling axis and cellular metabolism are hallmarks of prostate cancer. This study provides insight into both hallmarks by uncovering a novel link between AR and the pentose phosphate pathway (PPP). Specifically, we identify 6-phosphogluoconate dehydrogenase ( 6PGD ) as an androgen-regulated gene that is upregulated in prostate cancer. AR increased the expression of 6PGD indirectly via activation of sterol regulatory element binding protein 1 (SREBP1). Accordingly, loss of 6PGD, AR or SREBP1 resulted in suppression of PPP activity as revealed by 1,2- 13 C Competing Interests: JG, JH, NR, MM, LQ, RS, AH, JX, AH, JH, MC, IM, DL, LS, LB None, SI none (© 2021, Gillis et al.) |
References: | Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. (PMID: 12184808) Mol Cell. 2019 Dec 19;76(6):857-871.e9. (PMID: 31586547) Life Sci. 2018 Dec 1;214:124-135. (PMID: 30389439) Endocr Relat Cancer. 2016 May;23(5):R219-27. (PMID: 27130044) Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308) Oncogenesis. 2014 May 26;3:e103. (PMID: 24861463) Nature. 2014 Jun 12;510(7504):278-82. (PMID: 24759320) Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. (PMID: 25908785) Clin Cancer Res. 2012 Jul 1;18(13):3562-70. (PMID: 22573351) Chem Biol Interact. 2019 Sep 1;310:108722. (PMID: 31226286) J Cancer Prev. 2014 Dec;19(4):273-8. (PMID: 25574462) Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700) Oncogene. 2017 Jan 12;36(2):254-262. (PMID: 27270429) Oncotarget. 2013 May;4(5):691-704. (PMID: 23674566) Mol Cancer Ther. 2013 May;12(5):567-76. (PMID: 23493310) Cancer Discov. 2012 Apr;2(4):328-43. (PMID: 22576210) Adv Exp Med Biol. 2019;1210:185-237. (PMID: 31900911) Nat Biotechnol. 2012 Oct;30(10):918-20. (PMID: 23051804) Mol Oncol. 2018 Sep;12(9):1608-1622. (PMID: 30117261) Asian J Urol. 2020 Jul;7(3):203-218. (PMID: 33024699) Methods Mol Biol. 2016;1418:391-416. (PMID: 27008025) Oncol Lett. 2019 May;17(5):4213-4221. (PMID: 30944616) Transl Androl Urol. 2015 Jun;4(3):355-64. (PMID: 26816835) EBioMedicine. 2017 Apr;18:83-93. (PMID: 28412251) Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. (PMID: 25489091) Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998) N Engl J Med. 2014 Jul 31;371(5):424-33. (PMID: 24881730) Nat Genet. 2015 Nov;47(11):1346-51. (PMID: 26457646) J Cell Physiol. 2014 Jun;229(6):688-95. (PMID: 24129850) Mol Cell. 2007 Aug 3;27(3):380-92. (PMID: 17679089) Sci Rep. 2018 Feb 1;8(1):2090. (PMID: 29391407) Mol Cell. 2010 Jul 30;39(2):171-83. (PMID: 20670887) Mol Cell Endocrinol. 2003 Jul 31;205(1-2):21-31. (PMID: 12890564) Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616) J Steroid Biochem Mol Biol. 2019 Jul;191:105367. (PMID: 31051242) Endocr Relat Cancer. 2015 Oct;22(5):805-18. (PMID: 26187127) EMBO Mol Med. 2014 Apr;6(4):519-38. (PMID: 24497570) Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) Nat Rev Urol. 2020 Apr;17(4):214-231. (PMID: 32112053) Front Endocrinol (Lausanne). 2020 Jun 09;11:365. (PMID: 32582032) J Pathol. 2011 Jan;223(2):283-94. (PMID: 21125681) Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944) Genome Biol. 2013 Apr 25;14(4):R36. (PMID: 23618408) Eur J Pharmacol. 2015 Oct 5;764:124-133. (PMID: 26144377) Mol Carcinog. 2018 Aug;57(8):1055-1066. (PMID: 29668110) Urol Oncol. 2018 Oct;36(10):472.e21-472.e27. (PMID: 30119993) Pharmacol Res. 2018 May;131:177-184. (PMID: 29466694) Elife. 2021 Aug 12;10:. (PMID: 34382934) Asian J Urol. 2020 Jul;7(3):258-270. (PMID: 32742926) Mol Endocrinol. 2006 Oct;20(10):2265-77. (PMID: 16455816) Cell. 2015 Jul 16;162(2):454. (PMID: 28843286) Nat Commun. 2018 Mar 21;9(1):1176. (PMID: 29563510) Nat Cell Biol. 2015 Nov;17(11):1484-96. (PMID: 26479318) J Biol Chem. 2008 Oct 24;283(43):29341-54. (PMID: 18682402) Endocr Relat Cancer. 2016 Dec;23(12):T179-T197. (PMID: 27799360) Biochem Biophys Res Commun. 2005 Jun 24;332(1):288-96. (PMID: 15896329) |
فهرسة مساهمة: | Keywords: androgen receptor; cancer biology; human; pentose phosphate pathway; prostate cancer |
سلسلة جزيئية: | GEO GSE152254; GSE48403; GSE56288(GSM1358397); GSE56288(GSM1328950); GSE73994(GSM1907200); GSE91561(ENCFF911YFI); GSE31477(GSM935627;ENCFF000XXR) |
المشرفين على المادة: | 0 (AR protein, human) 0 (Receptors, Androgen) 0 (SREBF1 protein, human) 0 (Sterol Regulatory Element Binding Protein 1) EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases) EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1) EC 2.7.11.31 (AMP-Activated Protein Kinases) EC 6.4.1.2 (ACACA protein, human) EC 6.4.1.2 (Acetyl-CoA Carboxylase) H6PT94IV61 (physcione) KA46RNI6HN (Emodin) |
تواريخ الأحداث: | Date Created: 20210812 Date Completed: 20211021 Latest Revision: 20220107 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC8416027 |
DOI: | 10.7554/eLife.62592 |
PMID: | 34382934 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2050-084X |
---|---|
DOI: | 10.7554/eLife.62592 |